Cargando…

Efficacy and Safety Study of Low-Molecular-Weight Heparin and Fondaparinux Sodium After Hip Arthroplasty: A Retrospective Cohort Study

BACKGROUND: Low molecular heparin(LMWH) and sodium sulfadiazine heparin(FPX) are commonly used to prevent deep vein thrombosis(DVT) after total hip arthroplasty(THA). In this study, we compared the role of these drugs in preventing DVT after THA. METHODS: Patients who underwent unilateral THA at the...

Descripción completa

Detalles Bibliográficos
Autores principales:	Haibier, Abuduwupuer, Yusufu, Alimujiang, Lin, Hang, Kayierhan, Aiben, Abudukelimu, Yimuran, Abudurexiti, Tuerhongjiang
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove 2023
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10684995/ https://www.ncbi.nlm.nih.gov/pubmed/38033454 http://dx.doi.org/10.2147/ORR.S431372

Ejemplares similares

Effect of different cement distribution in bilateral and unilateral Percutaneous vertebro plasty on the clinical efficacy of vertebral compression fractures
por: Haibier, Abuduwupuer, et al.
Publicado: (2023)

Efficacy and safety of using aminocaproic acid and tranexamic acid during the perioperative period for treating trochanteric fractures in elderly femurs
por: Yusufu, Alimujiang, et al.
Publicado: (2023)

Comparison of the efficacy of low-molecular-weight heparin and fondaparinux sodium after total knee arthroplasty: a retrospective cohort study
por: Yang, Tianxiang, et al.
Publicado: (2023)

The Fondaparinux Paradox: Fondaparinux-Related Heparin-induced Thrombocytopenia
por: Vadi, Sonali, et al.
Publicado: (2018)

Fondaparinux sodium/heparin: Type II heparin-induced thrombocytopenia and drug cross reactivity: case report
Publicado: (2022)

Failure of Fondaparinux in Autoimmune Heparin-Induced Thrombocytopenia
por: Sartori, Michelangelo, et al.
Publicado: (2020)

Fondaparinux Sodium Compared With Low‐Molecular‐Weight Heparins for Perioperative Surgical Thromboprophylaxis: A Systematic Review and Meta‐analysis
por: Kumar, Arun, et al.
Publicado: (2019)

Fondaparinux sodium and low molecular weight heparin for venous thromboembolism prophylaxis in Chinese patients with major orthopedic surgery or trauma: a real-world study
por: Fu, Donglin, et al.
Publicado: (2022)

Novel, Precise, Accurate Ion-Pairing Method to Determine the Related Substances of the Fondaparinux Sodium Drug Substance: Low-Molecular-Weight Heparin
por: Deshpande, Amol A., et al.
Publicado: (2016)

Retrospective Analysis of Fondaparinux and Low-Molecular-Weight Heparin in the Treatment of Women With Recurrent Spontaneous Abortion
por: Zhao, Long, et al.
Publicado: (2021)

Fondaparınux Versus Nadroparın for Preventıon of Venous Thromboembolısm After Electıve Hıp and Knee Arthroplasty()
por: Argun, Mahmut, et al.
Publicado: (2013)

Effects of low molecular weight heparin and fondaparinux on mortality, hemorrhagic and thrombotic complications in COVID-19 patients
por: Fragkou, Paraskevi C., et al.
Publicado: (2022)

Fondaparinux: another potential treatment for heparin-induced thrombocytopenia type II?
por: Honore, Patrick M., et al.
Publicado: (2016)

Fondaparinux in heparin‐induced thrombocytopenia: A decade's worth of clinical experience
por: Schindewolf, Marc
Publicado: (2018)

Use of fondaparinux in a pregnant woman with pulmonary embolism and heparin-induced thrombocytopenia
por: Ciurzyński, Michał, et al.
Publicado: (2011)

Systematic review of fondaparinux for heparin‐induced thrombocytopenia: When there are no randomized controlled trials
por: Linkins, Lori‐Ann, et al.
Publicado: (2018)

Monitoring the appropriate prescription of low molecular weight heparins and Fondaparinux through administrative data. A retrospective observational study in the Tuscany region
por: Moretti, Giaele, et al.
Publicado: (2023)

The use of fondaparinux for the treatment of venous thromboembolism in a patient with heparin-induced thombocytopenia and thrombosis caused by heparin flushes
por: Spyropoulos, Alex C, et al.
Publicado: (2008)

Azd-1222/fondaparinux-sodium/heparin: Vaccine-induced immune thrombotic thrombocytopenia (VIIT), aggravation of VIIT and lack of efficacy: case report
Publicado: (2021)

Management of Heparin-Induced Thrombocytopenia with Fondaparinux in a Patient with Left Ventricular Assist Device
por: Velagic, V., et al.
Publicado: (2014)

Fondaparinux in a critically Ill patient with heparin-induced thrombocytopenia: A case report
por: He, Yumiao, et al.
Publicado: (2018)

Assay-Based Differentiation in the Neutralization Profile of Unfractionated Heparin, Enoxaparin, and Fondaparinux by Andexanet Alfa
por: Siddiqui, Fakiha, et al.
Publicado: (2020)

Unfractionated heparin and mechanical thromboprophylaxis in hip arthroplasty
por: Garcia, Flávio Luís, et al.
Publicado: (2015)

Fondaparinux Outpatient Use for Patients with a Heparin-Induced Thrombocytopenia History: A Case Report and Review
por: Christopher, Amy
Publicado: (2016)

Fondaparinux-associated Thrombocytopenia
por: Malik, Jahanzeb, et al.
Publicado: (2021)

Enoxaparin-sodium/fondaparinux-sodium: Major and clinically relevant bleeding complications: 8 case reports
Publicado: (2020)

Review of fondaparinux sodium injection for the prevention of venous thromboembolism in patients undergoing surgery
por: Bergqvist, David
Publicado: (2006)

AZD-1222/fondaparinux sodium: Thrombotic thrombocytopenia and lack of efficacy: case report
Publicado: (2021)

A retrospective evaluation of fondaparinux for confirmed or suspected heparin-induced thrombocytopenia in left-ventricular-assist device patients
por: Benken, Scott T, et al.
Publicado: (2014)

A case of probable bemiparin-induced heparin-induced thrombocytopenia type II managed with low-dose fondaparinux
por: Koul, AN
Publicado: (2015)

Effect of heparin and low-molecular weight heparin on serum potassium and sodium levels
por: Bengalorkar, Girish M., et al.
Publicado: (2011)

When Will Fondaparinux Induce Thrombocytopenia?
por: Chen, Li-Yu, et al.
Publicado: (2022)

Design and Synthesis of Neutralizable Fondaparinux
por: Zhang, Liangwei, et al.
Publicado: (2022)

Fondaparinux: Should It Be Studied in Patients with COVID-19 Disease?
por: Marongiu, Francesco, et al.
Publicado: (2020)

Fondaparinux for intra and perioperative anticoagulation in patients with heparin-induced thrombocytopenia candidates for peripheral vascular surgery: Report of 4 cases
por: Illuminati, Giulio, et al.
Publicado: (2016)

Adverse Drug Reactions Attributed to Fondaparinux and Unfractionated Heparin in Cardiovascular Care Unit: An Observational Prospective Pilot Study in a Tertiary Care Hospital
por: Sharma, Sahithi, et al.
Publicado: (2018)

A systematic review of clinical practice guidelines on the use of low molecular weight heparin and fondaparinux for the treatment and prevention of venous thromboembolism: Implications for research and policy decision-making
por: Johnston, Amy, et al.
Publicado: (2018)

Promising Drug Fondaparinux for the Treatment of COVID-19: an In Silico Analysis of Low Molecular Weight Heparin, Direct Oral Anticoagulant, and Antiplatelet Drug Interactions with Host Protease Furin
por: Ertan-Bolelli, Tugba, et al.
Publicado: (2022)

Fondaparinux for systemic anticoagulation during continuous hemofiltration in a patient with heparin-induced thrombocytopenia and limb ischemia – a case report
por: Osawa, Eduardo Atsushi, et al.
Publicado: (2022)

Management of acute coronary syndromes with fondaparinux
por: Wienbergen, Harm, et al.
Publicado: (2007)

Cannot write session to /tmp/vufind_sessions/sess_n1k8h9gqa4khcrrgvm850hv8bv